Diverse types of dermatologic toxicities from immune checkpoint blockade therapy-Reference-Cited by-同舟云学术

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

Published:2016-12-21 Issue:2 Volume:44 Page:158-176
ISSN:0303-6987
Container-title:Journal of Cutaneous Pathology
language:en
Short-container-title:J Cutan Pathol

Author:

Curry Jonathan L.¹²,Tetzlaff Michael T.¹,Nagarajan Priyadharsini¹,Drucker Carol²,Diab Adi³,Hymes Sharon R.²,Duvic Madeleine²,Hwu Wen-Jen³,Wargo Jennifer A.⁴,Torres-Cabala Carlos A.¹²,Rapini Ronald P.²,Prieto Victor G.¹²

Affiliation:

1. Department of Pathology, Section of Dermatopathology; The University of Texas MD Anderson Cancer Center; Houston TX USA

2. Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston TX USA

3. Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston TX USA

4. Department of Surgical Oncology; The University of Texas MD Anderson Cancer Center; Houston TX USA

Publisher

Wiley

Subject

Dermatology,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cup.12858/fullpdf

Reference70 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2014

3. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises;Massari;Cancer Treat Rev,2015

4. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab;McDermott;J Clin Oncol,2015

5. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer;Gettinger;J Clin Oncol,2015

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance;Frontiers in Immunology;2024-08-29

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient;Frontiers in Pharmacology;2024-08-13

4. Enfortumab vedotin‐induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature;Journal of Cutaneous Pathology;2024-07-15

5. Immune-related dermatological adverse events of antitumor immunotherapy with PD-1, PD-L1, CTLA-4 inhibitors;Russian Journal of Skin and Venereal Diseases;2024-05-14